Amancio Carnero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9267837/publications.pdf

Version: 2024-02-01

47006 9,860 187 47 citations h-index papers

91 g-index 192 192 192 15497 citing authors docs citations times ranked all docs

43889

#	Article	IF	CITATIONS
1	The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets, 2008, 8, 187-198.	1.6	685
2	A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity. Journal of Experimental Medicine, 1999, 190, 1375-1382.	8.5	564
3	Glycolytic enzymes can modulate cellular life span. Cancer Research, 2005, 65, 177-85.	0.9	458
4	PTEN, more than the AKT pathway. Carcinogenesis, 2007, 28, 1379-1386.	2.8	355
5	Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncology, The, 2013, 14, e358-e369.	10.7	313
6	Roscovitine Targets, Protein Kinases and Pyridoxal Kinase. Journal of Biological Chemistry, 2005, 280, 31208-31219.	3.4	312
7	p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biology, 2000, 2, 148-155.	10.3	266
8	The PKB/AKT Pathway in Cancer. Current Pharmaceutical Design, 2010, 16, 34-44.	1.9	252
9	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	2.8	239
10	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
11	The PIM Family of Serine/Threonine Kinases in Cancer. Medicinal Research Reviews, 2014, 34, 136-159.	10.5	191
12	NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduction and Targeted Therapy, 2021, 6, 2.	17.1	189
13	The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Frontiers in Oncology, 2014, 4, 252.	2.8	166
14	The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays, 2016, 38, S65-74.	2.5	164
15	Rho proteins induce metastatic properties in vivo. Oncogene, 1997, 15, 3047-3057.	5.9	153
16	CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene, 2005, 24, 5543-5551.	5.9	147
17	Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochemical Pharmacology, 2013, 85, 629-643.	4.4	137
18	The cancer stem-cell signaling network and resistance to therapy. Cancer Treatment Reviews, 2016, 49, 25-36.	7.7	122

#	Article	IF	CITATIONS
19	Identification of proteomic signatures associated with lung cancer and COPD. Journal of Proteomics, 2013, 89, 227-237.	2.4	116
20	Immortalization of Primary Human Prostate Epithelial Cells by c-Myc. Cancer Research, 2005, 65, 2179-2185.	0.9	112
21	<i>NAMPT</i> Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. Clinical Cancer Research, 2018, 24, 1202-1215.	7.0	106
22	DNA Methylation Signatures Identify Biologically Distinct Thyroid Cancer Subtypes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2811-2821.	3.6	100
23	High throughput screening in drug discovery. Clinical and Translational Oncology, 2006, 8, 482-490.	2.4	98
24	MOLECULAR GENETICS: MarX: An Approach to Genetics in Mammalian Cells. Science, 1999, 283, 1129-1130.	12.6	92
25	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. European Respiratory Journal, 2014, 43, 1740-1749.	6.7	91
26	Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene, 2010, 29, 2973-2982.	5.9	85
27	Chemical Genetic Analysis of FOXO Nuclear–Cytoplasmic Shuttling by Using Imageâ€Based Cell Screening. ChemBioChem, 2008, 9, 2229-2237.	2.6	79
28	Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases. Journal of Biological Chemistry, 2009, 284, 28392-28400.	3.4	77
29	Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Molecular Cancer, 2020, 19, 7.	19.2	72
30	Cold-Inducible RNA-Binding Protein Bypasses Replicative Senescence in Primary Cells through Extracellular Signal-Regulated Kinase 1 and 2 Activation. Molecular and Cellular Biology, 2009, 29, 1855-1868.	2.3	69
31	NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. Oncotarget, 2017, 8, 99514-99530.	1.8	67
32	S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis, 2008, 29, 2089-2095.	2.8	65
33	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	2.5	65
34	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer, 2014, 14, 656.	2.6	64
35	Markers of Cellular Senescence. Methods in Molecular Biology, 2013, 965, 63-81.	0.9	62
36	Cell cycle deregulation: a common motif in cancer. Progress in Cell Cycle Research, 2003, 5, 5-18.	0.9	62

#	Article	IF	Citations
37	PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 2007, 29, 491-499.	2.8	61
38	Newtrans-Platinum Drugs with Phosphines and Amines as Carrier Ligands Induce Apoptosis in Tumor Cells Resistant to Cisplatin. Journal of Medicinal Chemistry, 2007, 50, 2194-2199.	6.4	61
39	Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene, 2008, 27, 1961-1970.	5.9	59
40	Role of Mitochondria in Cancer Stem Cell Resistance. Cells, 2020, 9, 1693.	4.1	59
41	Cooperation between Cdk4 and p27kip1 in Tumor Development: A Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. Cancer Research, 2005, 65, 3846-3852.	0.9	55
42	MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis, 2007, 28, 2096-2104.	2.8	55
43	Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Letters, 2011, 300, 145-153.	7.2	53
44	The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clinical Cancer Research, 2017, 23, 3871-3883.	7.0	53
45	Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget, 2015, 6, 40557-40574.	1.8	53
46	Understanding FOXO, New Views on Old Transcription Factors. Current Cancer Drug Targets, 2010, 10, 135-146.	1.6	52
47	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-na $ ilde{A}$ -ve patients. Molecular Cancer Therapeutics, 2005, 4, 814-823.	4.1	50
48	FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. Journal of Thoracic Oncology, 2019, 14, 641-655.	1.1	50
49	Therapeutic targeting of replicative immortality. Seminars in Cancer Biology, 2015, 35, S104-S128.	9.6	49
50	MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis, 2007, 28, 1646-1652.	2.8	48
51	Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p $110\hat{l}\pm$ Predisposes Mammary Glands to Neoplastic Transformation. Cancer Research, 2008, 68, 9643-9653.	0.9	47
52	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	4.1	46
53	An HTS Approach to Screen for Antagonists of the Nuclear Export Machinery Using High Content Cell-Based Assays. Assay and Drug Development Technologies, 2007, 5, 333-342.	1.2	45
54	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	1.2	45

#	Article	IF	CITATIONS
55	MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival. PLoS ONE, 2013, 8, e56169.	2.5	45
56	Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis, 2007, 28, 584-594.	2.8	44
57	Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain. Oncotarget, 2015, 6, 41582-41599.	1.8	44
58	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood, 2007, 110, 3345-3351.	1.4	42
59	Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biology, 2009, 10, 14.	3.0	41
60	Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(ii) anticancer complexes. Dalton Transactions, 2009, , 3457.	3.3	41
61	Characterization of the p53 Response to Oncogene-Induced Senescence. PLoS ONE, 2008, 3, e3230.	2.5	41
62	Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle, 2011, 10, 2751-2762.	2.6	40
63	Extreme sensitivity to Yondelis \hat{A}^{\otimes} (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. Journal of Cellular Biochemistry, 2007, 100, 339-348.	2.6	39
64	Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene, 2004, 23, 6006-6011.	5.9	37
65	Association between the miRNA Signatures in Plasma and Bronchoalveolar Fluid in Respiratory Pathologies. Disease Markers, 2012, 32, 221-230.	1.3	37
66	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget, 2018, 9, 4395-4410.	1.8	37
67	Novel inhibitors of the PI3K family. Expert Opinion on Investigational Drugs, 2009, 18, 1265-1277.	4.1	36
68	Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. Oncotarget, 2016, 7, 63611-63628.	1.8	36
69	Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. Journal of Cellular Biochemistry, 2005, 95, 979-989.	2.6	35
70	The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis, 2012, 33, 1479-1486.	2.8	34
71	Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment. Oncogene, 2019, 38, 1309-1323.	5.9	34
72	ras-p21 Activates phospholipase D and A2, but not phospholipase C or PKC, inXenopus laevis Oocytes. Journal of Cellular Biochemistry, 1994, 54, 478-486.	2.6	33

#	Article	IF	CITATIONS
73	Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage. International Journal of Molecular Sciences, 2013, 14, 3440-3455.	4.1	33
74	Cellular Senescence as a Target in Cancer Control. Journal of Aging Research, 2011, 2011, 1-12.	0.9	32
75	Disruptive chemicals, senescence and immortality. Carcinogenesis, 2015, 36, S19-S37.	2.8	32
76	Levels of p27kip1 determine Aplidin sensitivity. Molecular Cancer Therapeutics, 2007, 6, 1310-1316.	4.1	31
77	Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle, 2011, 10, 1948-1955.	2.6	31
78	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene, 2016, 35, 2777-2788.	5.9	31
79	NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance. Frontiers in Oncology, 2019, 9, 292.	2.8	31
80	Phospholipase-induced maturation of Xenopus laevis oocytes: Mitogenic activity of generated metabolites. Journal of Cellular Biochemistry, 1993, 52, 440-448.	2.6	30
81	MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis, 2007, 28, 2443-2450.	2.8	30
82	The preparation and characterization of trans-platinum(iv) complexes with unusually high cytotoxicity. Dalton Transactions, 2011, 40, 344-347.	3.3	29
83	Proteomic biomarkers in lung cancer. Clinical and Translational Oncology, 2013, 15, 671-682.	2.4	29
84	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11 , 572-579.	2.4	28
85	Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. PLoS ONE, 2010, 5, e9305.	2.5	28
86	Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. PLoS ONE, 2013, 8, e60277.	2.5	28
87	The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Scientific Reports, 2016, 6, 38079.	3.3	28
88	Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget, 2015, 6, 6151-6159.	1.8	28
89	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget, 2016, 7, 33111-33124.	1.8	27
90	A genetic view of laryngeal cancer heterogeneity. Cell Cycle, 2016, 15, 1202-1212.	2.6	27

#	Article	IF	CITATIONS
91	Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Frontiers in Oncology, 2020, 10, 1533.	2.8	27
92	Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Disease Markers, 2012, 32, 221-30.	1.3	27
93	Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. International Journal of Cancer, 1995, 60, 235-243.	5.1	26
94	Bypassing cellular senescence by genetic screening tools. Clinical and Translational Oncology, 2010, 12, 410-417.	2.4	26
95	$p38\hat{l}\pm$ limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene, 2012, 31, 4447-4459.	5.9	26
96	MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFI® Activation in Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1454-1465.	4.1	26
97	The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Scientific Reports, 2018, 8, 2394.	3.3	26
98	MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. Oncotarget, 2015, 6, 12625-12636.	1.8	26
99	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis, 2007, 28, 1418-1425.	2.8	25
100	Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 2358-2366.	4.1	25
101	New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. Journal of Experimental and Clinical Cancer Research, 2019, 38, 234.	8.6	25
102	Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis, 2008, 29, 1343-1350.	2.8	24
103	Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget, 2017, 8, 58872-58886.	1.8	24
104	The TGF- \hat{l}^2 co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis, 2010, 31, 2145-2154.	2.8	23
105	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget, 2016, 7, 67033-67046.	1.8	23
106	3D and organoid culture in research: physiology, hereditary genetic diseases and cancer. Cell and Bioscience, 2022, 12, 39.	4.8	23
107	The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. European Journal of Medicinal Chemistry, 2010, 45, 134-141.	5.5	22
108	MAP17 and the double-edged sword of ROS. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 44-52.	7.4	22

#	Article	IF	CITATIONS
109	Cellular senescence or stemness: hypoxia flips the coin. Journal of Experimental and Clinical Cancer Research, 2021, 40, 243.	8.6	22
110	Oxidation of anticancer Pt(ii) complexes with monodentate phosphane ligands: towards stable but active Pt(iv) prodrugs. Chemical Communications, 2013, 49, 4806.	4.1	21
111	Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anti-Cancer Drugs, 2005, 16, 977-987.	1.4	20
112	Downâ€regulation of <i>spinophilin</i> in lung tumours contributes to tumourigenesis. Journal of Pathology, 2011, 225, 73-82.	4.5	20
113	The Cytoskeletal Adapter Protein Spinophilin Regulates Invadopodia Dynamics and Tumor Cell Invasion in Glioblastoma. Molecular Cancer Research, 2016, 14, 1277-1287.	3.4	20
114	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 195.	8.6	20
115	The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness. Cancers, 2020, 12, 254.	3.7	20
116	Progesterone but notras requires MPF for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of both signaling pathways. Journal of Cellular Biochemistry, 1994, 55, 465-476.	2.6	19
117	Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. Journal of Cellular Biochemistry, 2004, 92, 514-524.	2.6	19
118	Genetic modelling of the PTEN/AKT pathway in cancer research. Clinical and Translational Oncology, 2008, 10, 618-627.	2.4	19
119	Mouse Models to Decipher the PI3K Signaling Network in Human Cancer. Current Molecular Medicine, 2009, 9, 612-625.	1.3	19
120	IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF). Journal of Thoracic Oncology, 2016, 11, 2183-2192.	1.1	19
121	The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. Oncotarget, 2017, 8, 98580-98597.	1.8	19
122	Combined MEK and Pl3K/p $110\hat{l}^2$ Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research, 2020, 80, 843-856.	0.9	19
123	Spinophilin: A New Tumor Suppressor at 17q21. Current Molecular Medicine, 2012, 12, 528-535.	1.3	19
124	Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway. FEBS Letters, 1998, 422, 155-159.	2.8	18
125	Isolation of an Intermediate in the Platination ofp-Nitroacetophenone 4-Methylthiosemicarbazone: Potential Application as an Antitumor Drug. European Journal of Inorganic Chemistry, 2008, 2008, 1183-1187.	2.0	17
126	Epigenetic mechanisms in senescence, immortalisation and cancer. Biological Reviews, 2011, 86, 443-455.	10.4	17

#	Article	IF	CITATIONS
127	A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling. PLoS ONE, 2008, 3, e1823.	2.5	17
128	Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma. Clinical Cancer Research, 2013, 19, 3925-3935.	7.0	16
129	MAP17, a ROS-dependent oncogene. Frontiers in Oncology, 2012, 2, 112.	2.8	15
130	The second generation of iodido complexes: trans-[PtI2(amine)(amine′)] bearing different aliphatic amines. Journal of Inorganic Biochemistry, 2013, 127, 182-187.	3 . 5	15
131	Prognostic relevance of Src activation in stage II-III colon cancer. Human Pathology, 2017, 67, 119-125.	2.0	15
132	MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy. Oncotarget, 2018, 9, 32958-32971.	1.8	15
133	câ€MYB―and PGC1aâ€dependent metabolic switch induced by MYBBP1A loss in renal cancer. Molecular Oncology, 2019, 13, 1519-1533.	4.6	15
134	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	6.1	15
135	Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. Oncotarget, 2016, 7, 31723-31737.	1.8	15
136	EMX homeobox genes regulate microphthalmia and alter melanocyte biology. Experimental Cell Research, 2005, 311, 27-38.	2.6	14
137	PDGFRÎ \pm β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer, 2012, 12, 514.	2.6	14
138	Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases. Molecular Cancer, 2018, 17, 80.	19.2	14
139	Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. Oncotarget, 2017, 8, 105196-105210.	1.8	14
140	Prognostic relevance of estrogen receptor- \hat{l}_{\pm} Ser167 phosphorylation in stage II-III colon cancer patients. Human Pathology, 2014, 45, 2437-2446.	2.0	13
141	Overexpression of cyclin D1 inhibits TNF-induced growth arrest. Journal of Cellular Biochemistry, 2003, 89, 484-499.	2.6	12
142	Structureâ€"activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. Journal of Inorganic Biochemistry, 2007, 101, 551-558.	3 . 5	12
143	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, 2019, 131, 112-121.	2.0	12
144	Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer. Cancers, 2019, 11, 235.	3.7	12

#	Article	IF	Citations
145	Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells. Oncogenesis, 2020, 9, 96.	4.9	12
146	Influence of (Hydroxymethyl)pyridine and Pyridineâ€carboxylic Acids, in <i>trans</i> â€Position to the Isopropylamine and Ammine Ligands, on the Cytotoxicity of Platinum Complexes. Chemistry and Biodiversity, 2008, 5, 2090-2100.	2.1	11
147	Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer, 2014, 14, 281.	2.6	11
148	Genetic modification of hypoxia signaling in animal models and its effect on cancer. Clinical and Translational Oncology, 2015, 17, 90-102.	2.4	11
149	NUMB and NUMBL differences in gene regulation. Oncotarget, 2018, 9, 9219-9234.	1.8	11
150	Regulation of sarcomagenesis by the empty spiracles homeobox genes EMX1 and EMX2. Cell Death and Disease, 2021, 12, 515.	6.3	10
151	Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer. Cancers, 2021, 13, 4029.	3.7	10
152	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	2.8	9
153	Platinum(IV) Complexes of 3- and 4-Picolinic Acids Containing Ammine or Isopropylamine Ligands - Synthesis, CharacteriÂzation, X-ray Structures, and Evaluation of Their Cytotoxic Activity against Cancer Cell Lines. European Journal of Inorganic Chemistry, 2008, 2008, 4762-4769.	2.0	8
154	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduction and Targeted Therapy, 2020, 5, 195.	17.1	8
155	Microinjection of acylphosphatase blocksXenopus laevisoocytes maturation induced byras-p21. FEBS Letters, 1993, 326, 167-170.	2.8	7
156	Using cells devoid of RAS proteins as tools for drug discovery. Molecular Carcinogenesis, 2009, 48, 1038-1047.	2.7	7
157	Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-Homologues. Molecular Therapy, 2010, 18, 936-946.	8.2	7
158	The hypoxic microenvironment: A determinant of cancer stem cell evolution. Inside the Cell, 2016, 1, 96-105.	0.4	7
159	PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells, 2020, 9, 1071.	4.1	7
160	Senotherapeutics in Cancer and HIV. Cells, 2022, 11, 1222.	4.1	7
161	Acylphosphatase synergizes with progesterone during maturation ofXenopus laevisoocytes. FEBS Letters, 1993, 327, 265-270.	2.8	6
162	Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. Journal of Theoretical Biology, 2004, 230, 333-341.	1.7	6

#	Article	IF	Citations
163	Adding more content to screening: reactivation of FOXO as a therapeutic strategy. Clinical and Translational Oncology, 2009, 11, 651-658.	2.4	6
164	Empty spiracles homeobox genes EMX1 and EMX2 regulate WNT pathway activation in sarcomagenesis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 247.	8.6	6
165	Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget, 2018, 9, 19945-19960.	1.8	6
166	High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer. Oncotarget, 2015, 6, 30343-30356.	1.8	6
167	Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle. Cancers, 2021, 13, 2226.	3.7	5
168	Implications of maraviroc and/or rapamycin in a mouse model of fragility. Aging, 2020, 12, 8565-8582.	3.1	5
169	Cellular Senescence as a Target in Cancer Control. Current Cancer Therapy Reviews, 2007, 3, 7-15.	0.3	4
170	Synthesis, Reactivity Studies, and Cytotoxicity of Two trans-Iodidoplatinum(II) Complexes. Does Photoactivation Work?. Inorganics, 2018, 6, 127.	2.7	4
171	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2054.	3.7	4
172	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells, 2019, 8, 806.	4.1	3
173	Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells. Theranostics, 2021, 11, 3452-3471.	10.0	3
174	Cell cycle and cancer. , 2000, 2, 12-22.		3
175	Exploring cellular senescence as a tumor suppressor mechanism. , 2003, 5, 249-265.		3
176	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers, 2022, 14, 2202.	3.7	3
177	Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue. Journal of Cellular Biochemistry, 2005, 95, 859-867.	2.6	1
178	Cancer, Senescence, and Aging: Translation from Basic Research to Clinics. Journal of Aging Research, 2011, 2011, 1-2.	0.9	1
179	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. BMC Cancer, 2016, 16, 829.	2.6	1
180	Genome-Wide miRNA Screening for Genes Bypassing Oncogene-Induced Senescence. Methods in Molecular Biology, 2017, 1534, 53-68.	0.9	1

#	Article	IF	Citations
181	Between Bench and Bed Side: PI3K Inhibitors. Current Molecular Pharmacology, 2010, 3, 79-90.	1.5	1
182	SPINOPHILIN: A multiplayer tumor suppressor. Genes and Diseases, 2023, 10, 187-198.	3.4	1
183	PI3K pathway in cancer., 0,, 193-203.		O
184	Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 127-155.		0
185	MAP17 as Biomarker for Cancer Treatment. , 2014, , 1-10.		O
186	MAP17 as Biomarker for Cancer Treatment. Biomarkers in Disease, 2015, , 167-178.	0.1	0
187	Editor's Note: Immortalization of Primary Human Prostate Epithelial Cells by c-Myc. Cancer Research, 2022, 82, 2656-2656.	0.9	0